According to the ESCAT, only five molecular alterations are associated with BC treatment efficacy with the highest level of evidence (ESCAT I): ERBB2 amplification, germline BRCA1/2 mutations, PI3KCA mutations, microsatellite instability (MSI) and NTRK translocations. This evidence concerns the gene ERBB2 and breast cancer.